SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene.
Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe.
The results of this study will inform assessments for a future interventional treatment trial.
Full Title of Study: “Natural History Study in Prodromal and Manifest Huntington Disease Gene Expansion Carriers (HDGECs) – SHIELD HD”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 2022
The rationale for this study is to obtain longitudinal information related to Somatic Instability and DNA damage response genes in HDGECs at various stages of the disease. Established assessments of disease progression will also be recorded.
Clinical Trial Outcome Measures
- DDR gene expression
- Time Frame: 2 years
- To assess deoxyribonucleic acid (DNA) damage repair (DDR) gene expression in accessible biofluids and disease trajectories for established and novel biomarkers and clinical outcomes.
- Compare rates of change in biomarkers for disease progression
- Time Frame: 2 years
- To compare the rates of change for different outcomes and cytosine adenine guanine (CAG) age product (CAP) Scores.
Participating in This Clinical Trial
Key Inclusion Criteria
Patients who meet all of the following criteria will be eligible to participate in the study:
1. Capacity to comprehend the study objectives and procedures
2. Documentation of genetically confirmed disease by direct DNA testing, defined as a CAG repeat length ≥39 in the HTT gene
3. Ability to undergo and tolerate MRI scans
4. Ability to tolerate blood draws and lumbar punctures
Key Exclusion Criteria
Patients who meet any of the following criteria will be excluded from participation in the study:
1. Any conditions, including severe chorea and dementia, that would prevent either writing or performing pen and paper, tablet, or computer based tasks as determined by the Investigator
2. Treatment with an investigational drug within 30 days prior to screening or within 5 half lives of the investigational drug, whichever is longer
3. History of gene therapy or cell transplantation or any other experimental brain surgery
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 63 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Triplet Therapeutics, Inc.
- Medpace, Inc.
- Provider of Information About this Clinical Study
- Overall Official(s)
- Anne Rosser, PhD FRCP, Principal Investigator, Cardiff University
- Overall Contact(s)
- Irina A Antonijevic, MD PhD, (781) 299-7830, TripletTrials@triplettx.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.